Notable how well ONXX's Nexavar did in that trial, particularly with the KRAS mutations. But the market seems not to care, perhaps because the Nexavar combo trial in NSCLC previously failed, or perhaps because nobody is paying attention. But does give some encouragement for the current Nexavar NSCLC trials.
The Bert Vogelstein webcast (Conclusion: "We now understand cancer") is great:
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.